Annabel Samimy
Stock Analyst at Stifel
(3.42)
# 941
Out of 4,944 analysts
54
Total ratings
43.75%
Success rate
27.85%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Annabel Samimy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Initiates: Buy | $45 | $44.64 | +0.81% | 1 | Mar 26, 2025 | |
| GPCR Structure Therapeutics | Initiates: Buy | $50 | $19.16 | +160.96% | 1 | Jan 8, 2025 | |
| ALT Altimmune | Initiates: Buy | $18 | $3.74 | +381.28% | 1 | Jan 8, 2025 | |
| IVA Inventiva | Maintains: Buy | $20 → $17 | $4.02 | +322.89% | 4 | Nov 22, 2024 | |
| MBX MBX Biosciences | Initiates: Buy | $40 | $12.95 | +208.88% | 1 | Oct 8, 2024 | |
| KMDA Kamada | Initiates: Buy | $18 | $7.39 | +143.57% | 1 | Jul 3, 2024 | |
| PHAT Phathom Pharmaceuticals | Initiates: Buy | $24 | $10.48 | +129.01% | 1 | May 3, 2024 | |
| RGNX REGENXBIO | Maintains: Buy | $40 | $8.93 | +347.93% | 2 | Apr 12, 2024 | |
| VKTX Viking Therapeutics | Reiterates: Buy | $80 | $41.27 | +93.85% | 6 | Mar 15, 2024 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $225 → $230 | $117.12 | +96.38% | 8 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 → $25 | $6.51 | +284.02% | 1 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $18.05 | +93.91% | 1 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $65 | $26.58 | +144.54% | 3 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $700 → $275 | $9.88 | +2,683.40% | 4 | Jun 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $45 | $13.56 | +231.86% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $8 | $0.45 | +1,697.75% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $0.53 | +4,445.45% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $700 → $750 | $1.14 | +65,689.47% | 3 | Apr 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $25 → $24 | $42.64 | -43.71% | 7 | Apr 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $15 → $21 | $1.90 | +1,005.26% | 6 | Sep 18, 2019 |
Palvella Therapeutics
Mar 26, 2025
Initiates: Buy
Price Target: $45
Current: $44.64
Upside: +0.81%
Structure Therapeutics
Jan 8, 2025
Initiates: Buy
Price Target: $50
Current: $19.16
Upside: +160.96%
Altimmune
Jan 8, 2025
Initiates: Buy
Price Target: $18
Current: $3.74
Upside: +381.28%
Inventiva
Nov 22, 2024
Maintains: Buy
Price Target: $20 → $17
Current: $4.02
Upside: +322.89%
MBX Biosciences
Oct 8, 2024
Initiates: Buy
Price Target: $40
Current: $12.95
Upside: +208.88%
Kamada
Jul 3, 2024
Initiates: Buy
Price Target: $18
Current: $7.39
Upside: +143.57%
Phathom Pharmaceuticals
May 3, 2024
Initiates: Buy
Price Target: $24
Current: $10.48
Upside: +129.01%
REGENXBIO
Apr 12, 2024
Maintains: Buy
Price Target: $40
Current: $8.93
Upside: +347.93%
Viking Therapeutics
Mar 15, 2024
Reiterates: Buy
Price Target: $80
Current: $41.27
Upside: +93.85%
Jazz Pharmaceuticals
Mar 15, 2024
Maintains: Buy
Price Target: $225 → $230
Current: $117.12
Upside: +96.38%
Mar 8, 2024
Reiterates: Buy
Price Target: $23 → $25
Current: $6.51
Upside: +284.02%
Oct 5, 2023
Initiates: Buy
Price Target: $35
Current: $18.05
Upside: +93.91%
Aug 29, 2023
Maintains: Buy
Price Target: $60 → $65
Current: $26.58
Upside: +144.54%
Jun 26, 2023
Downgrades: Hold
Price Target: $700 → $275
Current: $9.88
Upside: +2,683.40%
Mar 7, 2023
Initiates: Buy
Price Target: $45
Current: $13.56
Upside: +231.86%
Nov 10, 2022
Upgrades: Buy
Price Target: $8
Current: $0.45
Upside: +1,697.75%
Aug 24, 2021
Initiates: Buy
Price Target: $24
Current: $0.53
Upside: +4,445.45%
Apr 16, 2020
Maintains: Buy
Price Target: $700 → $750
Current: $1.14
Upside: +65,689.47%
Apr 16, 2020
Maintains: Hold
Price Target: $25 → $24
Current: $42.64
Upside: -43.71%
Sep 18, 2019
Maintains: Hold
Price Target: $15 → $21
Current: $1.90
Upside: +1,005.26%